Immune-mediated renal pharmacology
Assess candidate activity in a mouse IgAN context when the platform is available for the required study window.
RENAL DISEASE MODEL
IgA Nephropathy (IgAN) Mouse Model
A mouse IgA nephropathy model is identified in the reviewed partner portfolio for immune-mediated renal disease research, with current availability confirmed case by case.
The reviewed partner documentation identifies the IgAN platform as under development, so current model status, induction design, study window, and endpoints are verified before placement.
MODEL OVERVIEW
An emerging mouse platform for immune-mediated IgA nephropathy research.
The partner model portfolio includes a mouse IgAN program alongside established chronic kidney disease and renal-hypertension models. IgAN study availability and technical details are confirmed during project review.
Therapeutic areaIgA nephropathy
SpeciesMouse
Model statusPartner platform, Verify availability
Typical useEfficacy, Pathology, Biomarkers
TYPICAL APPLICATIONS
What this model can support.
Renal pathology
Plan protocol-defined kidney tissue collection and pathology outputs around the biological question.
Biomarker strategy
Integrate fit-for-purpose renal or immune biomarkers when supported by the final study design.
PK/PD integration
Link exposure and pharmacodynamic measurements to renal readouts when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Renal phenotype
Protocol-defined disease and renal-function measurements for the confirmed model design.
Pathology
Kidney tissue collection and histopathology according to the final protocol.
Biomarkers
Renal, immune, or mechanism-linked biomarkers selected for the program.
Exposure
Systemic or renal tissue exposure when incorporated into the study.
Current partner documentation identifies this platform as under development. Availability, protocol, endpoints, and timeline must be confirmed during technical review before study placement.
STUDY DESIGN
Key factors aligned before execution.
- Current model availability
- Induction design and disease window
- Candidate mechanism
- Treatment route and schedule
- Renal pathology and biomarker plan
- PK/PD integration requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a IgAN study.Required fields are marked with an asterisk(*).